(-)-O-Acetyl-L-lactic aicd - CAS 6034-46-4
Main Product
Product Name:
(-)-O-Acetyl-L-lactic aicd
Catalog Number:
CAS Number:
Molecular Weight:
Molecular Formula:
Chemical Structure
CAS 6034-46-4 (-)-O-Acetyl-L-lactic aicd

Reference Reading

1.Evidence to suggest adoption of water exchange deserves broader consideration: Its pain alleviating impact occurs in 90% of investigators.
Cadoni S1, Liggi M1, Falt P1, Sanna S1, Argiolas M1, Fanari V1, Gallittu P1, Mura D1, Porcedda ML1, Smajstrla V1, Erriu M1, Leung FW1. World J Gastrointest Endosc. 2016 Jan 25;8(2):113-21. doi: 10.4253/wjge.v8.i2.113.
AIM: To determine whether observations were reproducible among investigators.
2.A cell-permeable tool for analysing APP intracellular domain function and manipulation of PIKfyve activity.
Guscott B1, Balklava Z1, Safrany ST2, Wassmer T3. Biosci Rep. 2016 Mar 2. pii: BSR20160040. [Epub ahead of print]
The mechanisms for regulating PIKfyve complex activity are currently emerging. The PIKfyve complex, consisting of the phosphoinositide kinase PIKfyve (also known as FAB1), VAC14 and FIG4, is required for the production of phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2). PIKfyve function is required for homeostasis of the endo/lysosomal system and is crucially implicated in neuronal function and integrity, as loss of function mutations in the PIKfyve complex lead to neurodegeneration in mouse models and human patients. Our recent work has shown that the intracellular domain of the Amyloid Precursor Protein (APP), a molecule central to the aetiology of Alzheimer's disease binds to VAC14 and enhances PIKfyve function. Here we utilise this recent advance to create an easy-to-use tool for increasing PIKfyve activity in cells. We fused APP's intracellular domain (AICD) to the HIV TAT domain, a cell permeable peptide allowing proteins to penetrate cells.
3.Delayed AICD therapy and cardiac arrest resulting from undersensing of ventricular fibrillation in a subject with hypertrophic cardiomyopathy-A case report.
Chin A1, Healey JS2, Ribas CS2, Nair GM3. Indian Pacing Electrophysiol J. 2015 Jul 29;15(2):121-4. doi: 10.1016/j.ipej.2015.07.009.
Defibrillation testing is no longer routinely performed after automatic implantable cardioverter-defibrillator (AICD) implantation. However, certain subjects undergoing AICD implantation may be at higher risk of undersensing of ventricular arrhythmias resulting in potentially fatal outcomes. We present the case of a 30-year-old woman with hypertrophic cardiomyopathy (HCM; 'asymmetric septal hypertophy' morphologic variant) and prophylactic AICD who experienced an out of hospital cardiac arrest. AICD interrogation revealed undersensing as a result of intermittent high amplitude electrograms during an episode of ventricular fibrillation (VF). The subject underwent replacement and repositioning of the AICD lead along with pulse generator replacement (that utilized a different VF sensing algorithm) with appropriate sensing of VF and successful defibrillation testing. The presence of intermittent high amplitude electrograms during episodes of VF in AICDs using the AGC function should be recognized as a situation that may necessitate interventions to prevent undersensing and consequent delay in therapy.